Supplementary Table 1 Comparison of treatment naive patients who received SMV- and/or SOF-based regimens or TVR- or BOC-based regimens

	SMV- and/or SOF-containing regimens	TVR- or BOC-containing regimens	P value
	Continuous: Median (IQR) / Categorical: n (%)		
n	204	68	-
Age, yr	59 (51-64)	58 (48-61)	0.13[a]
Race, black, n (%)	17 (8)	15 (22)	< 0.01[b]
Gender, female, n (%)	75 (37)	25 (37)	1.00[b]
BMI, kg/m²	27.1 (24.5-29.9)	26.9 (22.9-30.9)	0.87[c]
Diabetes, n (%)	40 (20)	14 (21)	0.86[b]
HCV viral load, log IU/mL	6.13 (5.50-6.55)	6.29 (5.75-6.66)	0.22[a]
Hemoglobin, g/dL	13.9 (12.7-15.1)	14.0 (13.2-15.1)	0.13[a]
Platelet, x 10³/μL	157 (95-213)	159 (120 -202)	0.82[c]
ALT, U/L	62 (37-109)	69 (45-105)	0.15[c]
AST, U/L	57 (35-109)	63 (41-109)	0.24[c]
Albumin, g/dL	4.0 (3.6-4.4)	4.2 (3.9-4.4)	0.04[a]
FIB-4 score	2.60 (1.46-5.83)	2.56 (1.73-4.99)	0.92[c]
FIB-4 ≥ 3.25	88 (43%)	29 (43%)	0.91[b]

[a]T-test; [b]Chi-square; [c]Mann-Whitney. SMV: Simeprevir; SOF: Sofosbuvir; TVR: Telaprevir; BOC: Boceprevir; IQR: Interquartile range; BMI: Body mass index; HCV: Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate transaminase.

Supplementary Table 2. Baseline characteristics of 484 patients with confirmed (470) or imputed (14) SVR12 data compared to 24 patients with no EOT data who were lost to follow-up.

	Total	LFU	p-value
	Continuous: Median (IQR) / Categorical: n (%)		
N	484	24	-
Treatment SMV/SOF ± RBV SOF/RBV SOF/PEG/RBV	172 (36%) 220 (46%) 92 (19%)	6 (25%) 14 (58%) 4 (17%)	0.24 [a]
Age, years	60 (54 – 64)	60 (54 – 65)	0.92 [b]
Race, black	69 (14%)	2 (8%)	0.56 [c]
Gender, female	174 (37%)	9 (41%)	0.66 [c]
BMI, kg/m²	27.8 (24.7 – 30.8)	27.1 (24.3 – 29.7)	0.63 [b]
Diabetes, n (%)	105 (22%)	6 (25%)	0.80 [c]
Naïve to treatment, n(%)	196 (41%)	8 (33%)	0.53 [c]
HCV viral load, log IU/mL	6.16 (5.61 – 6.58)	6.10 (5.35 – 6.51)	0.34 [d]
Hemoglobin, g/dL	13.0 (12.6 – 15.1)	13.8 (12.1 – 15.3)	0.89 [b]
Platelet, x10³/μL	143 (91 – 195)	149 (82 – 198)	0.86 [d]
ALT, U/L	63 (38 – 105)	71 (48 – 91)	0.67 [d]
AST, U/L	62 (38 – 99)	66 (40 – 90)	0.98 [d]
Total Bilirubin, mg/dL	0.7 (0.5 – 1.1)	0.7 (0.4 – 1.2)	0.90 [d]
Albumin, g/dL	0.7 (0.5 – 1.1)	0.7 (0.4 – 1.2)	0.95 [b]
FIB-4 ≥ 3.25	255 (54%)	12 (50%)	0.84 [c]

EOT, end-of-treatment; LFU, lost to follow up; IQR, interquartile range; SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin; PEG, pegylated interferon; BMI, body mass index; HCV, hepatitis C virus; ALT, alanine transaminase; AST aspartate transaminase

[a] Chi-square

[b] T-test

[c] Fisher

[d] Mann-Whitney

Supplementary Table 3. Baseline characteristics of patients who initiated therapy with SMV/SOF and SMV/SOF/RBV

	Total	SMV/SOF	SMV/SOF/RBV	p-value
	Continuous: Median (IQR) / Categorical: n(%)			
N	178	85	92	-
Age, years	61 (57 – 65)	61 (56 – 66)	62 (57 – 65)	0.99 [a]
Race, black	27 (15%)	14 (17%)	13 (14%)	0.82 [b]
Gender, female	67 (37%)	42 (84%)	31 (34%)	0.35 [b]
BMI, kg/m^2	27.6 (24.5 – 30.3)	28.2 (25.1 – 32.0)	27.1 (24.0 – 29.7)	0.17 [d]
Diabetes, n (%)	29 (16%)	14 (17%)	15 (16%)	1.00 [b]
Naïve to treatment	51 (28%)	30 (35%)	20 (22%)	0.07 [b]
PI failure	48 (27%)	13 (15%)	35 (38%)	<0.01 [c]
HCV viral load, log IU/mL	6.29 (5.80 – 6.76)	6.33 (5.78 – 6.77)	6.23 (5.87 – 6.71)	0.88 [a]
Hemoglobin, g/dL	13.9 (12.7 – 15.1)	13.8 (12.3 – 15.2)	14.0 (13.0 – 15.0)	0.42 [a]
Platelet, x10^3/μL	145 (94 – 191)	149 (85 – 205)	145 (99 – 175)	0.83 [d]
ALT, U/L	72 (45 – 102)	79 (47 – 122)	70 (45 – 113)	0.40 [d]
AST, U/L	70 (40 – 114)	63 (33 – 106)	76 (41 – 115)	0.41 [d]
Total Bilirubin, mg/dL	0.70 (0.50 – 1.00)	0.70 (0.5 – 1.1)	0.6 (0.5 – 1.0)	0.39 [d]
Albumin, g/dL	4.1 (3.7 – 4.4)	4.1 (3.8 – 4.4)	4.1 (3.7 – 4.4)	0.46 [d]
FIB-4 score	3.67 (1.91 – 6.10)	3.29 (1.92 – 6.39)	3.87 (1.95 – 5.99)	0.51 [d]
FIB-4 ≥ 3.25	94 (55%)	42 (52%)	55 (60%)	0.37 [b]

SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin; IQR, interquartile range; BMI, body mass index; PI, protease inhibitor; HCV, hepatitis C virus; ALT, alanine transaminase; AST aspartate transaminase
[a] T-test
[b] Chi-square

[c] Fisher
[d] Mann-Whitney